SS-31 (Elamipretide): The Cardiolipin-Targeting Mitochondrial Peptide in Clinical Trials

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is SS-31?

SS-31, known clinically as elamipretide and by development names including Bendavia and MTP-131, is a synthetic tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine(Dmt)-Lys-Phe-NH2. It belongs to the Szeto-Schiller (SS) peptide series developed by Dr. Hazel Szeto and Dr. Peter Schiller, designed to selectively target and concentrate within mitochondria — specifically at the inner mitochondrial membrane (IMM) where the electron transport chain (ETC) resides.

What makes SS-31 remarkable among mitochondrial-targeted compounds is its mechanism of action. Rather than functioning as a conventional antioxidant that scavenges ROS after they are produced, SS-31 addresses mitochondrial dysfunction at its source by stabilizing the lipid environment in which the ETC operates. Its primary molecular target is cardiolipin, a unique phospholipid found almost exclusively in the IMM that is essential for the structural and functional integrity of ETC supercomplexes. For broader context on mitochondrial peptides, see our guide to mitochondrial peptides.

Property	Detail
Generic Name	Elamipretide
Development Names	SS-31, Bendavia, MTP-131
Sequence	D-Arg-Dmt-Lys-Phe-NH2
Amino Acids	4 (tetrapeptide with non-natural amino acid Dmt)
Molecular Weight	~640 Da
Primary Target	Cardiolipin on inner mitochondrial membrane
Mitochondrial Enrichment	~1,000-5,000 fold concentration in mitochondria
Developer	Stealth BioTherapeutics / Larimar Therapeutics
FDA Status	Not approved; multiple clinical trials completed/ongoing

Mechanism of Action

SS-31's mechanism is centered on its interaction with cardiolipin, a four-acyl-chain phospholipid that constitutes approximately 20% of the IMM lipid content and plays irreplaceable roles in mitochondrial function.

Cardiolipin Binding and Stabilization

• Electrostatic targeting: The alternating aromatic-cationic motif of SS-31 (Arg-aromatic-Lys-aromatic) is selectively attracted to the anionic cardiolipin head groups through electrostatic interactions, while the aromatic residues (Dmt and Phe) penetrate the lipid bilayer, anchoring the peptide at the IMM surface.
• Cardiolipin peroxidation prevention: By binding to cardiolipin, SS-31 protects its polyunsaturated acyl chains from oxidative damage by ROS generated during electron transport. Cardiolipin peroxidation is an early and critical event in mitochondrial dysfunction and apoptosis initiation.
• ETC supercomplex stabilization: Cardiolipin serves as essential structural glue for electron transport chain supercomplexes (respirasomes) — the assembled complexes of Complexes I, III, and IV that optimize electron transfer efficiency. By maintaining cardiolipin integrity, SS-31 preserves supercomplex assembly and function.

Bioenergetic Consequences

• Improved coupling efficiency: Stabilized ETC supercomplexes exhibit improved electron transfer with reduced electron leak, resulting in more efficient ATP production per oxygen consumed and reduced ROS generation.
• ROS source reduction: Rather than scavenging ROS after production, SS-31 reduces ROS generation at its primary source — electron leak from Complexes I and III — a fundamentally different and potentially more effective approach.
• Cytochrome c interaction: SS-31 has been shown to optimize the interaction between cardiolipin and cytochrome c, preventing the conversion of cytochrome c from an electron carrier to a peroxidase — a key event in the mitochondrial apoptosis pathway.

Research and Clinical Trials

Barth Syndrome (TAZPOWER Trial)

Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene, which is essential for cardiolipin remodeling. Patients have abnormal cardiolipin profiles leading to severe cardiomyopathy, skeletal myopathy, and neutropenia. SS-31/elamipretide represents a rational therapy for Barth syndrome because it directly targets the cardiolipin dysfunction central to the disease.

The Phase 2 trial in Barth syndrome showed improvements in 6-minute walk test (6MWT) distance, cardiac stroke volume, and patient-reported outcomes. However, the Phase 3 TAZPOWER trial did not meet its primary endpoint (change in 6MWT), though secondary endpoints and subgroup analyses showed trends toward benefit. The small patient population (Barth syndrome is extremely rare) and endpoint challenges complicate interpretation.

Heart Failure

SS-31 was studied in heart failure with reduced ejection fraction (HFrEF) in the Phase 2 PROGRESS-HF trial. The trial evaluated the effect of elamipretide on left ventricular end-systolic volume (LVESV) measured by cardiac MRI. While the primary endpoint was not met, post-hoc analyses suggested potential benefits in subgroups, and the compound demonstrated a favorable safety profile in this patient population.

Primary Mitochondrial Myopathy

The MMPOWER trials evaluated elamipretide in patients with primary mitochondrial myopathy (PMM), a group of genetic disorders affecting mitochondrial function. The Phase 3 MMPOWER-3 trial assessed 6MWT as the primary endpoint. Results showed numerical improvement but did not achieve statistical significance, contributing to ongoing debate about optimal endpoint selection in mitochondrial disease trials.

Preclinical Aging Research

Extensive preclinical research has demonstrated SS-31's potential in age-related conditions beyond genetic mitochondrial disease. In aged animal models, SS-31 has improved cardiac diastolic function, skeletal muscle mitochondrial energetics, insulin sensitivity, kidney function, and cognitive performance. These findings support the hypothesis that mitochondrial dysfunction is a driver of aging and that targeting cardiolipin may address a fundamental mechanism.

Safety and Tolerability

Across clinical trials enrolling several hundred patients, elamipretide has demonstrated a generally favorable safety profile. The most common adverse effects are injection site reactions (subcutaneous administration) — pain, erythema, and induration at the injection site. Some patients reported headache, nausea, and fatigue. No significant organ toxicity, cardiac arrhythmias, or dose-limiting adverse events have been consistently reported.

The compound's selectivity for mitochondria — concentrating 1,000-5,000 fold in mitochondria relative to cytoplasm — may contribute to its favorable safety profile by limiting off-target effects in other cellular compartments.

Regulatory Status

Elamipretide has received FDA Fast Track designation and Orphan Drug designation for Barth syndrome, as well as Orphan Drug designation for primary mitochondrial myopathy and several other mitochondrial diseases. Despite these designations and multiple clinical trials, it has not yet received FDA approval for any indication. Stealth BioTherapeutics, the original developer, merged with Larimar Therapeutics, which continues clinical development. The regulatory path forward remains uncertain pending additional trial data and potential discussions with the FDA.